Is There a Chickenpox Vaccine? How It Works and Who Needs It

A chickenpox vaccine has been available since the 1990s, and it remains one of the most effective tools for preventing varicella-zoster virus infection. The vaccine uses a weakened, live form of the virus and is given in two doses during childhood in countries that include it in their routine immunization schedules, including the United States, Australia, Germany, and others. But not every country offers it routinely, the protection it delivers depends on how many doses you get, and the story extends well beyond childhood shots.

Where the Vaccine Came From

The chickenpox vaccine traces back to Japan in the 1970s, where Dr. Michiaki Takahashi developed the first live attenuated varicella vaccine in the world. The virus strain used was isolated from the blistering fluid of a child with typical chickenpox, and it was named the Oka strain after the child’s family name.¹ That same Oka strain, grown through successive passages in cell culture to weaken it, remains the basis of every chickenpox vaccine used globally today. Japan and South Korea licensed the vaccine in the 1980s, and the United States followed in 1995. Initially the U.S. recommended a single dose for children; a second dose was added in 2006 after it became clear that one shot left gaps in long-term protection.

How the Vaccine Produces Immunity

The vaccine contains a live but weakened version of the varicella-zoster virus. After injection, the attenuated virus replicates just enough to prompt your immune system to produce antibodies against it and to train immune cells to recognize it in the future. This dual response matters: antibodies help intercept the virus in the bloodstream, while T cells hunt down cells already infected with it. Both arms of the immune response play a role in keeping you from getting sick if you encounter the wild virus later.²

Children tend to mount a stronger immune response to a single dose than adults do. In studies comparing the two groups, children showed significantly higher T-cell responses six weeks after vaccination, while adults needed a second dose to reach comparable levels of immunity.³ That difference is one reason the two-dose schedule is especially important for adolescents and adults who missed vaccination as children.

How Well It Works

After 25 years of real-world monitoring in the United States, one dose of the varicella vaccine provides moderate protection, roughly in the range of 82 to 85 percent, against chickenpox of any severity, and complete protection against severe disease. Two doses push overall effectiveness higher by at least ten percentage points and further reduce outbreaks.⁴ A study of children in Spain found one-dose effectiveness of about 87 percent overall, climbing to 97 percent after a second dose. But the single-dose effectiveness faded over time, dropping considerably by the third year, whereas the second dose restored very high protection.⁵

Data from China tells a broadly similar story, though with lower absolute numbers: overall vaccine effectiveness of about 56 percent with one dose and roughly 82 percent with two doses.⁶ The gap between studies from different countries likely reflects differences in circulating virus strains, vaccine coverage rates, and how much virus people encounter in the community. The consistent takeaway across settings is that a single dose helps but wanes, and a second dose makes protection considerably more durable.

Who Needs the Vaccine

In countries with universal vaccination programs, the standard recommendation is for all children to receive two doses, the first around 12 to 15 months of age and the second between 4 and 6 years. But the vaccine isn’t just for young children.

Adults and adolescents who never had chickenpox and were never vaccinated are also candidates. In clinical trials involving people aged 13 to 54, a two-dose regimen given four to eight weeks apart led to seroconversion rates of 99 percent, meaning nearly all participants developed measurable antibodies.⁷ Adults do, however, show weaker long-term immunity compared to children who were vaccinated at a younger age. Antibodies to the virus were detectable in about 80 percent of vaccinated adults after one year and roughly 70 percent after two to six years. Even when breakthrough infection occurred in vaccinated adults, the disease was mild, giving the vaccine 100 percent effectiveness against severe illness.⁸

Certain groups are considered higher priority for catch-up vaccination: healthcare workers who may be exposed to infected patients, people who work closely with young children, women of childbearing age who plan future pregnancies, military recruits, and college students living in close quarters. Because the vaccine is a live virus, it’s generally not given to people with severely weakened immune systems or to those who are currently pregnant.

What Chickenpox Looked Like Before the Vaccine

It’s easy to forget how common and occasionally dangerous chickenpox was. In the United States during the 25 years before the vaccine was licensed, over 2,200 people died from varicella. While children made up the largest share of cases, the death rate was highest among adults and infants. By the early 1990s, adults had a risk 25 times greater than children aged 1 to 4 of dying from the disease, and most of those who died were previously healthy.⁹ Hospitalizations for primary chickenpox were around 4 per 100,000 people annually, with children under 15 accounting for more than half of those cases.¹⁰

Among school-age children in the pre-vaccine era, annual chickenpox incidence was strikingly high: roughly 10 percent of children aged 5 to 9 caught the disease each year.¹¹ Chickenpox was essentially an expected part of growing up, and the rare but real complications, including bacterial skin infections, pneumonia, and encephalitis, were an accepted cost.

Population-Level Impact Since Vaccination Began

Countries that introduced universal childhood vaccination have seen dramatic drops in chickenpox hospitalizations. In Germany, varicella hospitalization rates in children under 10 fell sharply after vaccination was introduced, with the biggest declines in regions with the highest vaccine coverage.¹² A time-series analysis from another country with routine vaccination found an estimated 88 percent reduction in varicella hospital discharges among children under 14 compared to what would have been expected without the program.¹³

A broader review of global data supports these findings, showing that universal vaccination programs consistently reduce both the incidence of disease and hospitalizations. There’s also evidence of herd immunity: as vaccination coverage rises, even unvaccinated people see some benefit because the virus has fewer hosts to circulate through.¹⁴

Using the Vaccine After Exposure

One of the vaccine’s more useful tricks is that it can work even after you’ve already been exposed to chickenpox, if you get it quickly enough. A Cochrane review of small trials found that when unvaccinated children were given the vaccine within three days of household exposure, only about 23 percent developed chickenpox compared to 78 percent who received a placebo or nothing. Among the vaccinated children who did get sick, most had mild disease with fewer lesions.¹⁵ The evidence for vaccination given more than three days after exposure is too thin to draw confident conclusions, so speed matters.

This makes post-exposure vaccination a practical option in settings like schools or daycare centers during outbreaks. During a varicella outbreak among students in Shanghai, for example, first-dose vaccination as post-exposure prophylaxis showed 100 percent effectiveness in previously unvaccinated students.¹⁶ For people who can’t receive the live vaccine, such as pregnant women or immunocompromised individuals, varicella-zoster immune globulin remains an alternative option for post-exposure protection.

Breakthrough Infections

No vaccine delivers perfect protection, and some vaccinated people do get chickenpox. Breakthrough varicella, defined as infection occurring more than 42 days after vaccination, tends to be considerably milder than the disease in unvaccinated individuals. Cases typically involve fewer skin lesions and less fever, though the atypical presentation can sometimes delay diagnosis.¹⁷ The two-dose schedule reduces breakthrough infections substantially compared to a single dose, which is one of the key reasons the second dose was added to the recommended schedule.

The Combination Vaccine and Febrile Seizures

The varicella vaccine is available either as a standalone shot or combined with the measles, mumps, and rubella vaccine as MMRV. The combination shot means one fewer injection for your child, which is appealing, but it comes with a specific consideration for the first dose. Studies have found that the risk of a fever-related seizure in the seven to ten days following the first dose of MMRV is about twice as high as when MMR and varicella are given as separate injections at the same visit.¹⁸ The absolute increase is small, roughly 3.5 extra seizures per 10,000 doses.

Febrile seizures are frightening to witness but are almost always harmless and resolve on their own. The overall benefit-risk profile of MMRV is still considered positive when factoring in fewer injections, better compliance, and higher coverage rates.¹⁹ In practice, some pediatricians give the first dose as separate MMR and varicella injections and use the combination MMRV for the second dose, when the febrile seizure risk is no longer elevated.

Safety Beyond Seizures

Large-scale post-licensure surveillance in the United States documented about 67.5 adverse event reports per 100,000 vaccine doses distributed, with the vast majority being minor. Rashes, usually small and blistering, accounted for more than half of all reports. Injection-site reactions were the other common complaint. Serious adverse events were rare, at roughly 2.9 per 100,000 doses.²⁰ Among those who developed rashes after vaccination and had their virus tested, about 61 percent turned out to be carrying the wild-type virus, meaning they had been exposed to natural chickenpox around the time of vaccination rather than reacting to the vaccine itself. About 31 percent had the vaccine strain.

Surveillance of the combination MMRV vaccine over a more recent ten-year period found a similar pattern of mostly mild reactions, including injection-site redness, swelling, and fever. Some statistically notable signals that had not been previously listed on the label were identified, such as febrile convulsions and vaccination failure, though these need to be interpreted in context. Surveillance systems pick up every report, not just those caused by the vaccine.²¹

Can the Vaccine Virus Spread to Others?

Because the chickenpox vaccine contains a live virus, a natural question is whether a vaccinated person can pass the virus on. The answer is yes, but it’s rare and the circumstances are narrow. Transmission has been documented in a handful of cases where a vaccinated individual developed a post-vaccination rash and then spread the vaccine strain to close household contacts. In one case, a healthy 12-month-old developed about 30 blistering lesions after vaccination, and 16 days later his pregnant mother developed roughly 100 lesions. Testing confirmed the virus was the vaccine strain.²² A similar case involved a vaccinated adult woman whose two children developed vaccine-type rashes after she had a post-vaccination rash of about 30 lesions.²³

The key factor appears to be the rash: transmission from vaccinees to household contacts is directly related to whether the vaccinated person develops skin lesions and how many they have. Among susceptible siblings exposed to a vaccinated person with a rash, about 17 percent showed evidence of infection, and 73 percent of those had mild illness. The contact illness was milder than typical chickenpox, with no sign that the weakened vaccine virus reverted to full virulence.²⁴ Since most vaccinated people never develop any rash at all, the real-world risk of spreading the vaccine virus is very low. Still, if someone in your household is pregnant or immunocompromised and you develop a rash after vaccination, it’s worth keeping some distance and letting a doctor know.

How Long Does Protection Last?

Immunity from the chickenpox vaccine is durable but not indefinite. A study of vaccinated healthcare workers found that an estimated half of them lost detectable antibodies after about nine years.²⁵ That doesn’t necessarily mean those people are fully unprotected, since immune memory cells can still mount a response even after antibody levels fall below the measurable threshold. But it does help explain why breakthrough cases tend to increase with time since the last dose and why the second dose matters so much for sustained protection.

Like the natural virus it was derived from, the Oka vaccine strain persists in nerve cells after vaccination. Research has shown that the vaccine strain can reactivate when antibody levels decline, much as wild-type varicella-zoster virus reactivates to cause shingles.²⁶ Whether this latent vaccine virus produces the same long-term shingles risk as natural infection has been a topic of ongoing study. Reviews of global vaccination data have not found a consistent link between widespread childhood vaccination and a rise in shingles rates among older adults.¹⁴

Countries That Don’t Routinely Vaccinate

Despite the vaccine’s track record, several high-income countries still don’t include it in their routine childhood schedules. The United Kingdom, Denmark, and France, among others, have opted not to offer universal chickenpox vaccination. The reasons vary. One historical concern was that by reducing chickenpox circulation among children, adults would get fewer natural immune boosts from exposure, potentially leading to more shingles cases in older people. As noted, the evidence on that link has been inconsistent. Economic modeling also plays a role: some countries weigh the cost of a two-dose program against the fact that chickenpox is usually a mild childhood illness in their populations. Cost-effectiveness analyses in other settings have found that universal vaccination can save substantial healthcare spending and prevent deaths, though results depend heavily on vaccine price and the number of doses required.²⁷

Telling the Vaccine Virus From the Wild One

When a vaccinated person develops a chickenpox-like rash, it’s sometimes important to know whether the culprit is the weakened vaccine strain or a wild-type virus picked up in the community. Laboratories can make that distinction by looking at a handful of specific genetic markers where the two differ. A sequencing method targeting four particular spots in the viral genome can reliably sort vaccine-derived from wild-type virus.²⁸ Newer approaches using rapid sequencing technology can make this call even when the amount of virus in the sample is low.²⁹ This isn’t something a routine doctor’s office does, but it matters in outbreak investigations, in cases involving immunocompromised patients, and when public health authorities need to know whether a cluster of illness is caused by vaccine failure or by a new chain of wild virus transmission.